BRAF and congenital fibrosarcoma: This kind of mutation is uncommon in IFS but had been described by Charo et al. in 2018 in a pregnant 32-year-old woman affected by a mid-jejunal gastrointestinal stromal tumor (GIST), which was resected, but, considering its teratogenic potential, a therapy with a B-RAF inhibitor like Imatinib or Vemurafenib was not recommended (13).